NeoGenomics (NASDAQ:NEO) Sets New 1-Year High After Analyst Upgrade

NeoGenomics, Inc. (NASDAQ:NEO)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Needham & Company LLC raised their price target on the stock from $19.00 to $22.00. Needham & Company LLC currently has a buy rating on the stock. NeoGenomics traded as high as $20.17 and last traded at $19.77, with a volume of 56031 shares changing hands. The stock had previously closed at $19.13.

Several other analysts have also issued reports on NEO. Wall Street Zen upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. Benchmark increased their target price on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a research report on Wednesday, July 15th. Finally, Zacks Research lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, NeoGenomics currently has an average rating of “Moderate Buy” and an average target price of $18.17.

Key Stories Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: BTIG upgraded NeoGenomics to Buy from Neutral, signaling improved confidence in the company’s outlook. BTIG upgrades NeoGenomics to Buy
• Positive Sentiment: Needham raised its price target to $22 from $19 and maintained a Buy rating, implying substantial upside from the referenced share price. Needham raises NeoGenomics price target
• Positive Sentiment: NeoGenomics issued third-quarter 2026 revenue guidance of $209 million, above the $205.8 million consensus estimate. Full-year revenue guidance of $802 million to $806 million was broadly in line with the $803.8 million consensus. The company’s latest reported quarter also exceeded revenue and EPS expectations, with revenue up 11.2% year over year.
• Positive Sentiment: Warren Stone was selected as the next CEO, providing a named successor and potentially reducing some uncertainty around the transition. Warren Stone named next NeoGenomics CEO
• Neutral Sentiment: Board changes are scheduled to take effect January 4, 2027, adding another governance transition for investors to monitor. NeoGenomics board changes
• Negative Sentiment: The stock fell sharply after the CEO succession announcement, despite the revenue beat and solid outlook. Investors appear concerned about execution risk, strategic continuity, and whether the leadership change could disrupt NeoGenomics’ growth trajectory. NeoGenomics falls on CEO succession plan

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC increased its stake in NeoGenomics by 26.2% in the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after acquiring an additional 2,549,545 shares during the period. First Trust Advisors LP acquired a new position in shares of NeoGenomics in the 1st quarter worth approximately $45,725,000. American Capital Management Inc. acquired a new position in shares of NeoGenomics in the 2nd quarter worth approximately $32,648,000. GW&K Investment Management LLC lifted its position in shares of NeoGenomics by 7.5% during the 4th quarter. GW&K Investment Management LLC now owns 2,238,767 shares of the medical research company’s stock worth $26,328,000 after buying an additional 155,882 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics by 9.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after buying an additional 225,588 shares during the period. 98.50% of the stock is owned by institutional investors.

NeoGenomics Trading Down 3.2%

The company has a 50 day moving average of $17.47 and a 200 day moving average of $13.00. The company has a current ratio of 3.60, a quick ratio of 3.35 and a debt-to-equity ratio of 0.48. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -39.92 and a beta of 1.79.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.02. The firm had revenue of $201.66 million during the quarter, compared to analyst estimates of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The business’s revenue for the quarter was up 11.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 earnings per share. As a group, research analysts anticipate that NeoGenomics, Inc. will post -0.09 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology.